Jazz Pharmaceuticals (Nasdaq: JAZZ) is expected to report Q2 earnings around Aug. 7. Here's what Wall Street wants to see.

The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals' revenues will expand 94.5% and EPS will improve 49.3%.

The average estimate for revenue is $125.6 million. On the bottom line, the average EPS estimate is $1.06.

Revenue details
Last quarter, Jazz Pharmaceuticals notched revenue of $108.4 million. GAAP reported sales were much higher than the prior-year quarter's $50.9 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.91. GAAP EPS of $0.48 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 92.3%, 220 basis points worse than the prior-year quarter. Operating margin was 38.4%, 600 basis points worse than the prior-year quarter. Net margin was 25.5%, 1,740 basis points worse than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $599.6 million. The average EPS estimate is $4.66.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 212 members out of 282 rating the stock outperform, and 70 members rating it underperform. Among 74 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give Jazz Pharmaceuticals a green thumbs-up, and 27 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals is outperform, with an average price target of $61.67.

Over the decades, small-cap stocks like Jazz Pharmaceuticals have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.